

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 25, 2023

Longboard Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

1-40192
(Commission File Number)

84-5009619
(IRS Employer
Identification No.)

4275 Executive Square, Suite 950
La Jolla, CA
(Address of Principal Executive Offices)

92037
(Zip Code)

Registrant's Telephone Number, Including Area Code: (858) 789-9283

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	LBPH	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

In this report, “we” and “our” refer to Longboard Pharmaceuticals, Inc.

Item 5.07 Submission of Matters to a Vote of Security Holders.

We held our 2023 Annual Stockholders' Meeting (the “Annual Meeting”) on May 25, 2023. At the Annual Meeting, our stockholders:

- (i) Elected three Class II directors named herein to hold office until our 2026 Annual Stockholders' Meeting.
- (ii) Ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

The tables below set forth the results of the vote of our stockholders for the Annual Meeting.

Proposal 1: The election of three Class II directors

Director Nominee	For	Withheld	Broker Non-Votes
Vincent E. Aurentz	14,728,717	2,922,032	1,978,804
Casey C. Lynch	13,117,562	4,533,187	1,978,804
Jane Tiller, MBChB, FRCPsych	13,117,582	4,533,167	1,978,804

Proposal 2: The ratification of the selection of KPMG LLP

Votes for approval	19,617,556
Votes against approval	474
Abstentions	11,523
Broker non-votes	N/A

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Longboard Pharmaceuticals, Inc.

Date: May 26, 2023

By: _____
/s/ Kevin R. Lind
Kevin R. Lind
President and Chief Executive Officer
